We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App





Double COVID-19 Vaccine Doses May Be Needed for Guaranteed Protection from Novel Coronavirus

By HospiMedica International staff writers
Posted on 22 Jul 2020
Print article
Illustration
Illustration
Two doses of a COVID-19 vaccine may be required for protecting the world from the coronavirus, although doubling the number of doses for each person could make it more difficult to immunize billions of people, according to a Bloomberg report.

Amidst the pandemic, producing a COVID-19 vaccine and administering even a single-dose to everyone across the world would be a mammoth task, whereas the need for double shots is bound to increase complexities involved in manufacturing and logistics. A two-shot vaccine will be tougher to distribute widely and put developing nations at a particular disadvantage. There could be even more challenges if the vaccine’s efficacy reduces over time and annual inoculation is required, as suggested by some experts.

The latest results from clinical studies of COVID-19 vaccine candidates being developed by the University of Oxford (Oxford, UK) in collaboration with AstraZeneca (Cambridgeshire, England) and by Moderna, Inc. (Cambridge, MA, USA) appear to suggest the need for a double-shot vaccine regimen. Both the COVID-19 vaccine candidates are undergoing final-stage testing with two doses, as per the Bloomberg report. However, Oxford researchers believe that some recipients may acquire protection from a single dose and the results could indicate that a single shot could provide protection for the majority of people. AstraZeneca is exploring other regimens, although the company appears to be following a two-dose strategy and the first readout of its final-stage tests is most likely to be from two doses. On the other hand, Merck (Kenilworth, NJ, USA) has been focusing purely on one-dose shots as they can be deployed more easily and seamlessly across the world in a global vaccination campaign.

Similarly, CanSino Biologics Inc.’s (Tianjin, China) fast-moving COVID-19 vaccine candidate appears to prioritize a two-dose regimen as it seems to have failed to generate a strong response in people with pre-existing immunity to the novel coronavirus used as the vector, with researchers considering the use of a booster shot three to six months after vaccination. Following the news that CanSino published Phase II results of its COVID-19 vaccine candidate Ad5-nCoV, Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, said, “With one dose, CanSino’s human adenovirus vector-based vaccine elicited receptor-binding and neutralizing antibodies in 508 patients peaking after 28 days. However, in the 52% of study participants that had a high pre-existing immunity to the viral vector, both types of antibodies were only at half the level than in the group with low-pre-existing immunity. A second dose of the vaccine might solve this issue, but on the other hand reduce the number of people who can be vaccinated.”

“Higher vaccine doses usually lead to more adverse events, so one solution might be for the elderly to generally receive two doses of the vaccine and younger people only one dose, to measure pre-existing Ad5-vector antibodies and then decide how many doses will be needed, or to add an adjuvant to boost the immune response,” added Rosenbaum.

Related Links:
University of Oxford
AstraZeneca
Moderna, Inc.
Merck
CanSino Biologics Inc.


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
New
Transcatheter Heart Valve
SAPIEN 3 Ultra
New
Computed Tomography System
Aquilion ONE / INSIGHT Edition

Print article

Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.